Core Molding Technologies Stock News

COLUMBUS, Ohio, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in medium- and heavy-duty truck, powersports, building products, and industrial and utilities industries across the United States, Canada and Mexico today r...

COLUMBUS, Ohio, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding,” “Core” or the “Company”), today announced the promotion of Michael J. Gayford to Chief Operating Officer (“COO”), effective immediately.

COLUMBUS, Ohio, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in medium- and heavy-duty trucks, powersports, building products, and industrial and utility industries across North America, announced today that it will h...

COLUMBUS, Ohio, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in medium- and heavy-duty truck, powersports, building products, and industrial and utilities industries across the United States, Canada and Mexico today r...

COLUMBUS, Ohio, July 07, 2026 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in medium- and heavy-duty truck, powersports, building products, and industrial and utility industries across the United States, Canada, and Mexico, today a...

Aarhus, Denmark, 17 June 2026 – NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announces that further safety and efficacy data from its Phase 2a SYNAPSE-CMT exploratory study evaluating ignaseclant in patients living with Charcot-Marie-Tooth disease (CMT) types 1 or 2 has been presented in a late-breaking o...